Abstract
Parenteral formulations, particularly intravascular ones, offer a unique opportunity for direct access to the bloodstream and rapid onset of drug action as well as targeting to specific organ and tissue sites. Parenteral preparation have been traditionally used to accomplish these tasks and there are several products on the market using these injectable & control release novel drug & implant formulations. The broader application of these novel control drug delivary systems in parenteral drug delivery, however, particularly with new chemical entities, has been limited due primarily to the following reasons: a) only a small number of parenteral drug excipients are approved, b) there is increasing number of drugs that are partially or not soluble in conventional oils and other lipid solvents, and c) the ongoing requirement for site-specific targeting and controlled drug release. Thus, there is growing need to expand the array of targetable control drug delivery & drug implant systems to deliver a wide variety of drugs and produce stable formulations which can be easily manufactured in a sterile form, are cost effective and at least as safe and efficacious as the earlier developed systems. These advanced parenteral implant-based systems are at various stages of preclinical and clinical development which include nanoemulsions, nanosuspensions, liposomes, niosomes, nano partical, micro partical,pro- drug and needal free injection. This review article will showcase these injectable controlled release systems, advanced parenteral drug delivary system,implant&novel technologies in implant, recent innovations in sterile drug delivery devices and discuss advances in relation to formulation development, processing and manufacturing, and stability assessment.
